Medical Condition News

RSS

Popular low carbohydrate diet leads to increase in cholesterol levels

A 25 year study in Northern Sweden, published in BioMed Central's open access journal Nutrition Journal, is the first to show that a regional and national dietary intervention to reduce fat intake, decreased cholesterol levels, but a switch to the popular low carbohydrate diet was paralleled by in an increase in cholesterol levels.

11 Jun 2012

$27 million received to speed new treatments for disabling neurological disorder

The Johns Hopkins University School of Medicine has announced receipt of a five-year, $27 million gift earmarked to fast-track the development of therapies to treat tumors associated with neurofibromatosis type 1 (NF1), a common and often debilitating neurogenetic disorder that causes tumors called plexiform neurofibromas to grow on nerves anywhere in the body.

11 Jun 2012

Distinct cancer 'signatures' may help predict response to estrogen-lowering therapy

Decoding the DNA of patients with advanced breast cancer has allowed scientists to identify distinct cancer "signatures" that could help predict which women are most likely to benefit from estrogen-lowering therapy, while sparing others from unnecessary treatment.

11 Jun 2012

Rapid test to identify patients not responding to painkiller tramadol

French researchers have found a way to identify quickly the 5-10% of patients in whom the commonly used painkiller, tramadol, does not work effectively. A simple blood test can produce a result within a few hours, enabling doctors to switch a non-responding patient on to another painkiller, such as morphine, which will be able to work in these patients.

11 Jun 2012

Positive results from Cara’s CR845 Phase II study on acute post-operative pain

Cara Therapeutics, Inc. today announced positive results from a Phase II study for the treatment of acute post-operative pain with its novel, peptide-based, peripherally-acting kappa opioid agonist, CR845.

11 Jun 2012

Powerful new tools can study glycans’ function

Scientists at The Scripps Research Institute have developed chemical compounds that can make key modifications to common sugar molecules ("glycans"), which are found on the surface of all cells in our body. The new study presents powerful new tools for studying these molecules' function, for example in cell signaling and immunity, and for investigating new treatments for chronic inflammation, autoimmune diseases, cancer metastasis, and related conditions.

11 Jun 2012

Advance's Summer College Institute to take place from August 5-12

Advance LA announced today its newest program, The Summer College Institute. This innovative program will take place August 5-12, 2012, on the campus of American Jewish University in Los Angeles.

11 Jun 2012

FDA clears Nexstim’s new module for use with NBS System

Nexstim Oy, a medical device company, announced today that the U.S. Food and Drug Administration (FDA) has cleared the NexSpeech module for use with the Navigated Brain Stimulation (NBS) System.

11 Jun 2012

Ampio’s CRO completes Optina clinical trial for DME

Ampio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, whose lead drugs treat inflammatory diseases, including osteoarthritis and complications of Diabetes Mellitus such as diabetic macular edema (and others) announced today that it's CRO has completed analysis of the primary end point in the Optina clinical trial for DME conducted at St Michael Diabetes Hospital in Toronto Canada.

11 Jun 2012

Short sleep periods increase risk of stroke in normal-weight adults

Habitually sleeping less than six hours a night significantly increases the risk of stroke symptoms among middle-age to older adults who are of normal weight and at low risk for obstructive sleep apnea (OSA), according to a study of 5,666 people followed for up to three years.

11 Jun 2012

Data from first feasibility study of artificial pancreas system

Results from the first feasibility study of an advanced first-generation artificial pancreas system were presented today at the 72nd Annual American Diabetes Association Meeting in Philadelphia. Findings from the study indicated that the Hypoglycemia-Hyperglycemia Minimizer (HHM) System was able to automatically predict a rise and fall in blood glucose and correspondingly increase and/or decrease insulin delivery safely.

11 Jun 2012

Nanocontainers can fight against atherosclerosis

In Switzerland, more than 20,000 people (37% of all deaths) die of cardiovascular disease caused by atherosclerosis each year. Treatment options are currently available to people who suffer from the disease but no drug can target solely the diseased areas, often leading to generalized side effects.

11 Jun 2012

Simple blood test can quickly identify 'poor metabolisers'

11 Jun 2012

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin 10 mg demonstrated significant reductions in blood sugar levels (glycosylated hemoglobin levels, or HbA1c) compared with placebo at 24 weeks when either agent was added to existing sitagliptin therapy (with or without metformin) in adult patients with type 2 diabetes.

11 Jun 2012

Researchers identify six genes that predispose to migraine without aura

Researchers studied genetic data of more than 11 000 people and found altogether six genes that predispose to migraine without aura. Four of these genes are new and two of them confirm previous findings.

11 Jun 2012

MRI scans reveal how sleep deprivation impairs brain regions associated with food processing

MRI scans from a study being presented today at SLEEP 2012 reveal how sleep deprivation impairs the higher-order regions in the human brain where food choices are made, possibly helping explain the link between sleep loss and obesity that previous research has uncovered.

11 Jun 2012

Zafgen announces new data from two Phase 1 studies of beloranib on obesity

Zafgen, Inc., the world's first biopharmaceutical company dedicated to addressing the unmet need of severely obese patients, today announced new data from two Phase 1 studies of beloranib, a selective methionine aminopeptidase 2 inhibitor (MetAP2), which showed significant weight loss and improvements in cardiometabolic risk markers in severely obese women.

11 Jun 2012

Researchers identify new mitochondrial protein complex linked with type 2 diabetes

Researchers at Metabolic Solutions Development Company, LLC (MSDC) have identified a mitochondrial protein complex through which anti-diabetic drugs exert their insulin sensitizing effects when used to treat patients diagnosed with type 2 diabetes.

11 Jun 2012

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Sanofi announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c - glycated hemoglobin - reduction with Lantus (insulin glargine [rDNA origin] injection) versus sitagliptin.

11 Jun 2012

Study reviews data on influence of contralateral carotid occlusion on CEA and CAS

A new study, presented at the 66th Vascular Annual Meeting presented by the Society for Vascular Surgery (SVS) reviewed data on the influence of contralateral carotid occlusion (CCO) on carotid endarterectomy (CEA) and carotid artery stenting (CAS) for which there is a paucity of conflicting data.

11 Jun 2012